Login / Signup

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Markus JoergerEmiliano CalvoHeinz LaubliJuanita LopezGuzmán AlonsoElena Corral de la FuenteDagmar HessDavid KönigVicky Sanchez PerezChristoph BucherSangeeta JethwaElena Garralda
Published in: Journal for immunotherapy of cancer (2023)
NCT04855929.
Keyphrases
  • endothelial cells
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • diffuse large b cell lymphoma
  • multiple myeloma
  • randomized controlled trial
  • hodgkin lymphoma
  • pluripotent stem cells
  • study protocol